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high-risk (stage IIB/C, III) and metastatic (stage IV) melanoma.
METHODS: Data were acquired from Convergence CT, a
company that links longitudinal electronic medical records and
claims data from large physician practices, clinics, ambulatory
centers, and hospitals in the US. Subjects with 1 diagnosis of
malignant melanoma (ICD-9 172.xx, 173.xx, V10.82) from July
1, 2003 November 30, 2006 and pathology-conﬁrmed disease
stage of IIB/C, III, or IV were selected. Additional stage IV
patients were identiﬁed based on evidence of a subsequent ICD-9
code (197.xx, 198.xx) for secondary metastases. Post-diagnosis
prevalence of the key treatments was analyzed descriptively.
Logistic regression was used to assess predictors of therapeutic
choice. RESULTS: A total of 268 subjects were identiﬁed. Stage
distribution was: IIB/C (18%); III (21%); IV (61%). 58% were
65 years of age and 62% were male. Surgery was the predomi-
nant treatment in stage IIB/C and III (received by >80% of
subjects), but was seen in only 38% of stage IV patients. Across
all stages, radiation, chemotherapy, and immunotherapy were
less common (23%, 27%, and 10%, respectively). Being elderly
[odds ratio = 2.19; 95% CI = (1.10–4.35)] and having stage IV
disease [7.31 (2.38–22.39)] was associated with a signiﬁcantly
increased likelihood of receiving no active treatment. Older age
(65+), higher co-comorbidity burden, and having stage IV disease
were associated with a decreased probability of surgery [0.55
(0.30–0.99), 0.92 (0.86–0.99), 0.08 (0.03–0.22), respectively].
Receiving radiation was reduced by older age, but increased by
having stage IV disease [2.38 (0.91–6.22)]. Signiﬁcant predictors
of chemotherapy were stage IV disease [2.65 (1.01–6.93)] and
higher co-morbidity burden [1.08 (1.01–1.17)]. Finally,
increasing age substantially reduced the likelihood of receiving
immunotherapy [0.24 (0.10–0.60)]. CONCLUSION: Factors
inﬂuencing practice patterns and treatment choice in a popula-
tion with high risk or metastatic melanoma. Across therapeutic
choices, age and disease stage were the signiﬁcant predictors.
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OBJECTIVE: Using 12 years of administrative data, we assessed
the trends in the use of breast conserving surgery (BCS) before
and after the release of clinical guidelines on BCS in Japan
(published in 1999 and updated in 2005.) METHODS: We used
a database from the Quality Improvement/Indicator Project that
involved 40 teaching hospitals in Japan. Data on all discharged
cases were collected from these hospitals from 1995. We then
selected female operable breast cancer patients who were
admitted to ﬁve of these hospitals from January 1996 through
September 2007 (n = 1971). A multiple regression analysis was
performed to examine whether the proportion of the use of BCS
after publication of guidelines was higher than that before pub-
lication, after adjusted for the effects of patient’s age, comorbid-
ity status (Charlson Comorbidity Index), hospital, and time
period of admission. The Hosmer-Lemeshow test was conducted
to assess the goodness-of-ﬁt of the model. RESULTS: The pro-
portion of BCS use increased from 16.1% in 1996 to 62.2% in
2007. Multiple logistic regression analysis revealed that patients
who were <50 years old (P < 0.001) and had no comorbidity
(P < 0.001) were signiﬁcantly more likely to receive BCS. The
proportion of BCS use has been substantially higher since 2001,
two years after the BCS guidelines were published in Japan.
Signiﬁcant practice variations of BCS use were also conﬁrmed
among hospitals. CONCLUSION: This study conﬁrmed the lag
time between guideline publication and change in practice of BCS
use. We further need to examine the potential barriers to guide-
line adoption related to physicians’ knowledge and attitudes as
well as external barriers including patient-, guideline-, and
environment-related factors, to explain the reasons of change in
the use of BCS over ten years.
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OBJECTIVE: To document real-world treatment patterns in
elderly patients with high-risk (stage IIB/C, IIIA/B, IIIC) or meta-
static (stage IV) melanoma. METHODS: Data was taken from
the Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked database combining clinical information on
incident cancer cases in the US between 1991 and 2002 with
longitudinal (1991–2005) Medicare claims. Subjects 65 years
with 1 stage IIB or higher melanoma diagnosis and 6 months
of subsequent beneﬁts coverage were selected. We documented
utilization patterns of four major therapies (surgery, radiation,
chemotherapy, immunotherapy) following the diagnosis.
RESULTS: A total of 6470 subjects met all criteria. Stage distri-
bution was: IIB/C (38%); IIIA/B (46%); IIIC (1%); IV (15%).
Median follow-up was 56, 39, 16, and 6 months, respectively.
Surgery (primarily tumor excision) was the predominant 1st line
treatment, received by >85% of subjects with stage IIB/C, IIIA/B,
or IIIC melanoma and 60% of stage IV cases, but was a rare 2nd
line approach. Radiation was 1st line treatment in only 2%, 5%,
and 13% of stage IIB/C, IIIA/B, and IIIC cases, respectively,
but was more common as a 2nd line approach in these subjects
(15%, 24%, and 41%, respectively). Radiation was equally
prevalent (~30% of cases) as 1st or 2nd line treatment in stage IV.
Chemotherapy was uncommon as 1st line treatment (<4% of all
cases), but prevalent as 2nd line therapy (by respective stage,
14%, 20%, 41%, and 22% of cases). Immunotherapy was rare,
except as 2nd line treatment in stage IIIC (26% of cases). CON-
CLUSION: Beyond surgery as a 1st line approach, relatively few
patients received other types of treatment as either 1st or 2nd line
therapy. These ﬁndings demonstrate an unmet need in high risk
and metastatic melanoma. Additional analyses of administrative
data characterizing real-world treatment patterns in melanoma
are needed to help inform the direction of future clinical trials.
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OBJECTIVE: Numerous randomized controlled trials (RCTs)
have evaluated efﬁcacy of proton-pump inhibitors (PPIs) in con-
trolling nighttime symptoms of gastroesophageal reﬂux disease
(GERD). Quantitative synthesis of the effect of PPIs on nighttime
symptoms is lacking, thus the validity of performing a meta-
analysis was assessed. METHODS: MEDLINE and EMBASE
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